| n (%) . | Japanese subgroup . | Overall population . | ||
|---|---|---|---|---|
| AAP (n = 35) . | Placebo (n = 35) . | AAP (n = 597) . | Placebo (n = 602) . | |
| Patients eligible for subsequent therapya | 21 | 33 | 394 | 517 |
| Patients with subsequent therapy for PC | 18 (85.7) | 30 (90.9) | 244 (61.9) | 355 (68.7) |
| Bicalutamide | 10 (47.6) | 23 (69.7) | 57 (14.5) | 97 (18.8) |
| Docetaxel | 10 (47.6) | 19 (57.6) | 144 (36.5) | 212 (41.0) |
| Enzalutamide | 7 (33.3) | 23 (69.7) | 57 (14.5) | 99 (19.1) |
| Cabazitaxel | 5 (23.8) | 9 (27.3) | 25 (6.3) | 50 (9.7) |
| Radium Ra 223 dichloride | 5 (23.8) | 6 (18.2) | 27 (6.9) | 44 (8.5) |
| Dexamethasone | 2 (9.5) | 6 (18.2) | 9 (2.3) | 16 (3.1) |
| Flutamide | 2 (9.5) | 7 (21.2) | 5 (1.3) | 21 (4.1) |
| Abiraterone | 1 (4.8) | 12 (36.4) | 16 (4.1) | 84 (16.2) |
| n (%) . | Japanese subgroup . | Overall population . | ||
|---|---|---|---|---|
| AAP (n = 35) . | Placebo (n = 35) . | AAP (n = 597) . | Placebo (n = 602) . | |
| Patients eligible for subsequent therapya | 21 | 33 | 394 | 517 |
| Patients with subsequent therapy for PC | 18 (85.7) | 30 (90.9) | 244 (61.9) | 355 (68.7) |
| Bicalutamide | 10 (47.6) | 23 (69.7) | 57 (14.5) | 97 (18.8) |
| Docetaxel | 10 (47.6) | 19 (57.6) | 144 (36.5) | 212 (41.0) |
| Enzalutamide | 7 (33.3) | 23 (69.7) | 57 (14.5) | 99 (19.1) |
| Cabazitaxel | 5 (23.8) | 9 (27.3) | 25 (6.3) | 50 (9.7) |
| Radium Ra 223 dichloride | 5 (23.8) | 6 (18.2) | 27 (6.9) | 44 (8.5) |
| Dexamethasone | 2 (9.5) | 6 (18.2) | 9 (2.3) | 16 (3.1) |
| Flutamide | 2 (9.5) | 7 (21.2) | 5 (1.3) | 21 (4.1) |
| Abiraterone | 1 (4.8) | 12 (36.4) | 16 (4.1) | 84 (16.2) |
Abbreviations: AAP: abiraterone acetate plus prednisone; n: number of patients and PC: prostate cancer.
Patients who discontinued from study treatment and were still alive to receive subsequent therapy by the given clinical cut-off date.
| n (%) . | Japanese subgroup . | Overall population . | ||
|---|---|---|---|---|
| AAP (n = 35) . | Placebo (n = 35) . | AAP (n = 597) . | Placebo (n = 602) . | |
| Patients eligible for subsequent therapya | 21 | 33 | 394 | 517 |
| Patients with subsequent therapy for PC | 18 (85.7) | 30 (90.9) | 244 (61.9) | 355 (68.7) |
| Bicalutamide | 10 (47.6) | 23 (69.7) | 57 (14.5) | 97 (18.8) |
| Docetaxel | 10 (47.6) | 19 (57.6) | 144 (36.5) | 212 (41.0) |
| Enzalutamide | 7 (33.3) | 23 (69.7) | 57 (14.5) | 99 (19.1) |
| Cabazitaxel | 5 (23.8) | 9 (27.3) | 25 (6.3) | 50 (9.7) |
| Radium Ra 223 dichloride | 5 (23.8) | 6 (18.2) | 27 (6.9) | 44 (8.5) |
| Dexamethasone | 2 (9.5) | 6 (18.2) | 9 (2.3) | 16 (3.1) |
| Flutamide | 2 (9.5) | 7 (21.2) | 5 (1.3) | 21 (4.1) |
| Abiraterone | 1 (4.8) | 12 (36.4) | 16 (4.1) | 84 (16.2) |
| n (%) . | Japanese subgroup . | Overall population . | ||
|---|---|---|---|---|
| AAP (n = 35) . | Placebo (n = 35) . | AAP (n = 597) . | Placebo (n = 602) . | |
| Patients eligible for subsequent therapya | 21 | 33 | 394 | 517 |
| Patients with subsequent therapy for PC | 18 (85.7) | 30 (90.9) | 244 (61.9) | 355 (68.7) |
| Bicalutamide | 10 (47.6) | 23 (69.7) | 57 (14.5) | 97 (18.8) |
| Docetaxel | 10 (47.6) | 19 (57.6) | 144 (36.5) | 212 (41.0) |
| Enzalutamide | 7 (33.3) | 23 (69.7) | 57 (14.5) | 99 (19.1) |
| Cabazitaxel | 5 (23.8) | 9 (27.3) | 25 (6.3) | 50 (9.7) |
| Radium Ra 223 dichloride | 5 (23.8) | 6 (18.2) | 27 (6.9) | 44 (8.5) |
| Dexamethasone | 2 (9.5) | 6 (18.2) | 9 (2.3) | 16 (3.1) |
| Flutamide | 2 (9.5) | 7 (21.2) | 5 (1.3) | 21 (4.1) |
| Abiraterone | 1 (4.8) | 12 (36.4) | 16 (4.1) | 84 (16.2) |
Abbreviations: AAP: abiraterone acetate plus prednisone; n: number of patients and PC: prostate cancer.
Patients who discontinued from study treatment and were still alive to receive subsequent therapy by the given clinical cut-off date.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
